A Comparison of Adherence Rates to Ritonavir and Its Accompanying Protease Inhibitor

Completed

Conditions studied: HIV Infections

In brief

Pharmacologic boosting of protease inhibitors with ritonavir has become standard practice in antiretroviral therapy. Patients are instructed to take ritonavir at the same time as its accompanying protease inhibitor. However, ritonavir is unpopular with many patients because of its large size and because of the recommended need for refrigeration. This study will test the hypothesis that adherence to ritonavir is inferior to adherence to its accompanying protease inhibitor in patients receiving such therapy.

Key facts

Study ID

NCT00432783

Run by

Montefiore Medical Center

People needed

45

Starts

2006-06-01

Expected to finish

2007-08-01

Last updated by the study team

2018-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV infection, age>18 years, receiving therapy with ritonavir-boosted atazanavir or fosamprenavir, willingness to use MEMS caps, willingness to provide informed consent

You may not qualify if…

• Treatment with any medication that is contraindicated in combination with ritonavir or its accompanying protease inhibitor

Where it is running

• Montefiore Medical Center — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.